⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ABBV News
ABBVIE INC.
NAYA Therapeutics Announces World-Class Board of Directors
accessnewswire.com
AMGN
NVAX
MRK
CDXS
ABBV
ALGS
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
globenewswire.com
GMAB
ABBV
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
globenewswire.com
GMAB
ABBV
Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
globenewswire.com
GMAB
ABBV
Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)
globenewswire.com
GMAB
ABBV
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
globenewswire.com
GMAB
ABBV
Alloy Therapeutics Enters Into Agreement to Advance Novel Antibody Discovery Platform
businesswire.com
ABBV
ALOY
Chainguard Launches Commercial Builds with Industry Leaders, Setting a New Standard for Verifiable, Zero-Vulnerability Software
prnewswire.com
ESTC
GLBZ
GRAF
TIGR
SNOW
FTNT
HPE
OPEN
CHKP
CAN
PANW
CRWD
ZS
DDOG
MDB
SMCI
AMD
NVDA
INTC
AMZN
GOOG
MSFT
IBM
ORCL
CRM
ADBE
PYPL
NFLX
CMCSA
DIS
VZ
T
KO
PEP
JNJ
PG
XOM
CVX
UNH
JPM
BAC
WFC
C
GS
MS
AMGN
GILD
BMY
PFE
MRK
ABBV
LLY
MDT
ISRG
COST
WMT
HD
MCD
SBUX
NKE
BA
CAT
GE
HON
RTX
LMT
GD
MMC
AXP
V
MA
MSCI
ADP
AMAT
ASML
QCOM
AVGO
TXN
ADSK
CDNS
SNPS
MRVL
GOOGL
Allergan Aesthetics Redefines Skin Quality Communication with Launch of Skin Quality Index
prnewswire.com
ABBV
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
globenewswire.com
GMAB
ABBV